Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
September 02, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
August 13, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at JMP Securities CNS Forum

WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
August 03, 2020 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
July 27, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020

WALTHAM, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
July 01, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexantCorporate...
June 01, 2020 08:00 ET | Source: Minerva Neurosciences, Inc

REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
May 29, 2020 09:20 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259,...
May 04, 2020 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates

WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
April 27, 2020 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020

WALTHAM, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...